Your browser doesn't support javascript.
loading
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis.
Gómez-Pérez, Ana María; Ruiz-Limón, Patricia; Salas-Salvadó, Jordi; Vioque, Jesús; Corella, Dolores; Fitó, Montse; Vidal, Josep; Atzeni, Alessandro; Torres-Collado, Laura; Álvarez-Sala, Andrea; Martínez, María Ángeles; Goday, Albert; Benaiges, David; García-Gavilán, Jesús; Bernal López, María Rosa; Moreno-Indias, Isabel; Tinahones, Francisco J.
Afiliação
  • Gómez-Pérez AM; Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, the Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), University of Malaga, Malaga, Spain.
  • Ruiz-Limón P; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Salas-Salvadó J; Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, the Biomedical Research Institute of Malaga and Platform in Nanomedicine (IBIMA-BIONAND Platform), University of Malaga, Malaga, Spain.
  • Vioque J; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Corella D; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Fitó M; Department of Biochemistry and Biotechnology, Human Nutrition Unit, University of Rovira I Virgili, Reus, Spain.
  • Vidal J; Human Nutrition Unit, Pere I Virgili Health Research Institute (IISPV), Reus, Spain.
  • Atzeni A; Institute of Health and Biomedical Research of Alicante, University of Miguel Hernández (ISABIAL-UMH), Alicante, Spain.
  • Torres-Collado L; CIBER Epidemiology and Public Health (CIBERESP), Carlos III Health Institute, Madrid, Spain.
  • Álvarez-Sala A; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Martínez MÁ; Department of Preventive Medicine, University of Valencia, Valencia, Spain.
  • Goday A; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Benaiges D; Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital Del Mar Research Institute (IMIM), Barcelona, Spain.
  • García-Gavilán J; Endocrinology and Nutrition Department, Clinic University Hospital, Barcelona, Spain.
  • Bernal López MR; Endocrinology and Nutrition Department, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Moreno-Indias I; CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain.
  • Tinahones FJ; Department of Biochemistry and Biotechnology, Human Nutrition Unit, University of Rovira I Virgili, Reus, Spain.
Gut Microbes ; 15(1): 2223339, 2023.
Article em En | MEDLINE | ID: mdl-37345236
ABSTRACT
To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis-4 score (FIB-4) between baseline and one year of intervention. One-year changes in HSI were tertile 1 (T1) (-24.9 to -7.51), T2 (-7.5 to -1.86), T3 (-1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB-4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB-4 tertile of change T1 (-89.60 to -5.57), T2 (-5.56 to 11.4), and T3 (11.41 to 206.24). FIB-4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB-4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations.
What You Need to KnowWhat is the contextObesity and metabolic syndrome have been associated with nonalcoholic fatty liver disease (NAFLD). Gut microbiota and its interaction with the environment may play a key role in NAFLD.What is newMediterranean diet and physical activity can modify the scores for liver steatosis (HSI) and liver fibrosis (FIB−4) in only one year. A relation between the changes in these scores and gut microbiota changes was found.What is the impactThe discovery of microbiota-based biomarkers for NAFLD and the development of strategies to modulate gut microbiota in the treatment of NAFLD.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Síndrome Metabólica / Hepatopatia Gordurosa não Alcoólica / Microbioma Gastrointestinal Limite: Humans Idioma: En Revista: Gut Microbes Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Síndrome Metabólica / Hepatopatia Gordurosa não Alcoólica / Microbioma Gastrointestinal Limite: Humans Idioma: En Revista: Gut Microbes Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha